Baas I O, van den Berg F M, Mulder J W, Clement M J, Slebos R J, Hamilton S R, Offerhaus G J
Department of Pathology, Academic Medical Center, Amsterdam, Netherlands.
J Pathol. 1996 Mar;178(3):264-7. doi: 10.1002/(SICI)1096-9896(199603)178:3<264::AID-PATH485>3.0.CO;2-#.
Immunohistochemistry (IHC) for intranuclear p53 gene product is a simple, routine alternative to molecular genetic analysis of the p53 gene. Several methods for antigen enhancement are currently in use for IHC. This study evaluates the effect of extreme antigen enhancement for p53, using a monoclonal antibody (DO7) and a polyclonal antibody (CM1). The cases studied were five colorectal carcinomas, two specimens of normal colorectal mucosa, and four colorectal carcinomas with genetic alterations which are expected to preclude p53 gene product expression, namely mutation to a STOP codon in the p53 gene detected by denaturing gradient gel electrophoresis with subsequent sequencing and allelic loss of 17p in the region where p53 is located, detected by restriction fragment length polymorphism analysis. The findings suggest that extreme antigen enhancement may cause false-positive results with a distinct nuclear staining pattern when MAb DO7 is used as a primary antibody. It is concluded that all antigen enhancement methods should be thoroughly tested to evaluate their validity and that there may be a limit to the extent to which antigen enhancement can be applied in IHC for p53 protein.
细胞核内p53基因产物的免疫组织化学(IHC)检测是p53基因分子遗传学分析的一种简单、常规的替代方法。目前有几种抗原增强方法用于免疫组织化学检测。本研究使用单克隆抗体(DO7)和多克隆抗体(CM1)评估了p53极端抗原增强的效果。研究的病例包括5例结直肠癌、2例正常结直肠黏膜标本,以及4例预期会排除p53基因产物表达的基因改变的结直肠癌,即通过变性梯度凝胶电泳及后续测序检测到p53基因突变为终止密码子,以及通过限制性片段长度多态性分析检测到p53所在区域17p等位基因缺失。研究结果表明,当使用单克隆抗体DO7作为一抗时,极端抗原增强可能会导致假阳性结果,并伴有明显的核染色模式。得出的结论是,所有抗原增强方法都应进行全面测试以评估其有效性,并且在p53蛋白免疫组织化学检测中,抗原增强的应用程度可能存在限制。